Modulation of Δ9-tetrahydrocannabinol-induced MCF-7 breast cancer cell growth by cyclooxygenase and aromatase

Toxicology

Volumn 259, Issue 1-2, 2009, Pages 25-32

  Takeda, Shuso ^a   Yamamoto, Ikuo ^b   Watanabe, Kazuhito ^a  

^a HOKURIKU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

9 Tetrahydrocannabinol; Aromatase; Breast cancer; Cyclooxygenase 2; Estrogen; MCF 7 cells

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; ALPHA NAPHTHOFLAVONE; AMINOGLUTETHIMIDE; ARACHIDONIC ACID; AROMATASE; CANNABIDIOLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DRONABINOL; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; CANNABIS; ESTRADIOL; TETRAHYDROCANNABINOL;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; BREAST TUMOR; CHEMISTRY; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CANNABIS SATIVA;

ARACHIDONIC ACID; AROMATASE; BREAST NEOPLASMS; CANNABIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; SIGNAL TRANSDUCTION; TETRAHYDROCANNABINOL;

EID: 63149189746     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2009.01.024     Document Type: Article

References (55)

1. Angus W.G., Larsen M.C., and Jefcoate C.R. TCDD elevates erbB2 expression and signaling in T47D cells by reversing serum potentiation of estrogen receptor activity, independent of estrogen levels and enhanced ER down-regulation. Mol. Cell. Endocrinol. 170 (2000) 1-13
2. Antoniotti S., Maggiora P., Dati C., and De Bortoli M. Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro. Eur. J. Cancer 28 (1992) 318-321
3. Aramaki H., Tomiyasu N., Yoshimura H., and Tsukamoto H. Forensic chemical study on marihuana. I. A detection method of the principal constituents by thin-layer and gas chromatographies. Chem. Pharm. Bull. 16 (1968) 822-826
4. 9-tetrahydrocannabinol content and number of puffs. J. Pharmacol. Exp. Ther. 261 (1992) 114-122
5. Ben-Rafael Z., Mastroianni Jr. L., Meloni F., Lee M.S., and Flickinger G.L. Total estradiol, free estradiol, sex hormone-binding globulin, and the fraction of estradiol bound to sex hormone-binding globulin in human follicular fluid. J. Clin. Endocrinol. Metab. 63 (1986) 1106-1111
6. Brueggemeier R.W., Hackett J.C., and Diaz-Cruz E.S. Aromatase inhibitors in the treatment of breast cancer. Endocr. Rev. 26 (2005) 331-345
7. Campbell D.R., and Kurzer M.S. Flavonoid inhibition of aromatase enzyme activity in human preadipocytes. J. Steroid Biochem. Mol. Biol. 46 (1993) 381-388
8. Castagnetta L.A., Lo Casto M., Granata O.M., Polito L., Calabrò M., Lo Bue A., Bellavia V., and Carruba G. Estrogen content and metabolism in human breast tumor tissues and cells. Ann. NY Acad. Sci. 784 (1996) 314-324
9. Chagin A.S., Chrysis D., Takigawa M., Ritzen E.M., and Sävendahl L. Locally produced estrogen promotes fetal rat metatarsal bone growth; an effect mediated through increased chondrocyte proliferation and decreased apoptosis. J. Endocrinol. 188 (2006) 193-203
10. Choi H.K., Yang J.W., and Kang K.W. Bifunctional effect of resveratrol on the expression of ErbB2 in human breast cancer cell. Cancer Lett. 242 (2006) 198-206
11. Dannenberg A.J., Lippman S.M., Mann J.R., Subbaramaiah K., and DuBois R.N. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J. Clin. Oncol. 23 (2005) 254-266
12. Dempke W., Rie C., Grothey A., and Schmoll H.J. Cyclooxygenase-2: a novel target for cancer chemotherapy?. J. Cancer Res. Clin. Oncol. 127 (2001) 411-417
13. Díaz-Cruz E.S., Shapiro C.L., and Brueggemeier R.W. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J. Clin. Endocrinol. Metab. 90 (2005) 2563-2570
14. Fokialakis N., Lambrinidis G., Mitsiou D.J., Aligiannis N., Mitakou S., Skaltsounis A.L., Pratsinis H., Mikros E., and Alexis M.N. A new class of phytoestrogens; evaluation of the estrogenic activity of deoxybenzoins. Chem. Biol. 11 (2004) 397-406
15. Gierse J.K., Hauser S.D., Creely D.P., Koboldt C., Rangwala S.H., Isakson P.C., and Seibert K. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem. J. 305 (1995) 479-484
16. Hart S., Fischer O.M., and Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res. 64 (2004) 1943-1950
17. Howe L.R. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res. 9 (2007) 210
18. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., and Pertwee R.G. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54 (2002) 161-202
19. Hwang D., Scollard D., Byrne J., and Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Natl. Cancer Inst. 90 (1998) 455-460
20. Ishii Y., Miyoshi A., Watanabe R., Tsuruda K., Tsuda M., Yamaguchi-Nagamatsu Y., Yoshisue K., Tanaka M., Maji D., Ohgiya S., and Oguri K. Simultaneous expression of guinea pig UDP-glucuronosyltransferase 2B21 and 2B22 in COS-7 cells enhances UDP-glucuronosyltransferase 2B21-catalyzed morphine-6-glucuronide formation. Mol. Pharmacol. 60 (2001) 1040-1048
21. Johansson E., Norén K., Sjövall J., and Halldin M.M. Determination of delta 1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry. Biomed. Chromatogr. 3 (1989) 35-38
22. Jordan V.C. Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. Annu. Rev. Pharmacol. Toxicol. 35 (1995) 195-211
23. Kuruto-Niwa R., Ito T., Goto H., Nakamura H., Nozawa R., and Terao Y. Estrogenic activity of the chlorinated derivatives of estrogens and flavonoids using a GFP expression system. Environ. Toxicol. Pharmacol. 23 (2007) 121-128
24. Lee S.Y., Oh S.M., Lee S.K., and Chung K.H. Antiestrogenic effects of marijuana smoke condensate and cannabinoid compounds. Arch. Pharm. Res. 28 (2005) 1365-1375
25. Lewis J.S., Osipo C., Meeke K., and Jordan V.C. Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J. Steroid Biochem. Mol. Biol. 94 (2005) 131-141
26. Lewysohn O., Cordova T., Nimrod A., and Ayalon D. The suppressive effect of delta-1-tetrahydrocannabinol on the steroidogenic activity of rat granulosa cells in culture. Horm. Res. 19 (1984) 43-51
27. Ligresti A., Moriello A.S., Starowicz K., Matias I., Pisanti S., De Petrocellis L., Laezza C., Portella G., Bifulco M., and Di Marzo V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J. Pharmacol. Exp. Ther. 318 (2006) 1375-1387
28. Martin L.A., Farmer I., Johnston S.R., Ali S., and Dowsett M. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. Endocr. Relat. Cancer 12 (2005) S75-S84
29. McKallip R.J., Nagarkatti M., and Nagarkatti P.S. Δ-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J. Immunol. 174 (2005) 3281-3289
30. Miki Y., Suzuki T., Tazawa C., Yamaguchi Y., Kitada K., Honma S., Moriya T., Hirakawa H., Evans D.B., Hayashi S., Ohuchi N., and Sasano H. Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. Cancer Res. 67 (2007) 3945-3954
31. Notarnicola M., Messa C., Orlando A., Bifulco M., Laezza C., Gazzerro P., and Caruso M.G. Estrogenic induction of cannabinoid CB1 receptor in human colon cancer cell lines. Scand. J. Gastroenterol. 43 (2008) 66-72
32. Pasqualini J.R., Chetrite G., Blacker C., Feinstein M.C., Delalonde L., Talbi M., and Maloche C. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab. 81 (1996) 1460-1464
33. Press M.F., Bernstein L., Thomas P.A., Meisner L.F., Zhou J.Y., Ma Y., Hung G., Robinson R.A., Harris C., El-Naggar A., Slamon D.J., Phillips R.N., Ross J.S., Wolman S.R., and Flom K.J. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J. Clin. Oncol. 15 (1997) 2894-2904
34. Pino A.M., Rodríguez J.M., Ríos S., Astudillo P., Leiva L., Seitz G., Fernández M., and Rodríguez J.P. Aromatase activity of human mesenchymal stem cells is stimulated by early differentiation, vitamin D and leptin. J. Endocrinol. 191 (2006) 715-725
35. Rado A., Crystle C.D., and Townsley J.D. Concentration of estrogens in maternal peripheral plasma in late pregnancy, during labor and post partum. J. Clin. Endocrinol. Metab. 30 (1970) 497-503
36. Russell K.S., and Hung M.C. Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. Cancer Res. 52 (1992) 6624-6629
37. Santen R.J., and Harvey H.A. Use of aromatase inhibitors in breast carcinoma. Endocr. Relat. Cancer 6 (1999) 75-92
38. Singh A., Purohit A., Coldham N.G., Ghilchik M.W., and Reed M.J. Biochemical control of breast aromatase. Breast Cancer Res. Treat. 49 (1998) S9-S14 (Discussion S33-S37)
39. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
40. Smith C.J., Zhang Y., Koboldt C.M., Muhammad J., Zweifel B.S., Shaffer A., Talley J.J., Masferrer J.L., Seibert K., and Isakson P.C. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 13313-13318
41. Sonne-Hansen K., and Lykkesfeldt A.E. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line. J. Steroid Biochem. Mol. Biol. 93 (2005) 25-34
42. Su B., Díaz-Cruz E.S., Landini S., and Brueggemeier R.W. Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition. Steroids 73 (2008) 104-111
43. Takeda S., Ishii Y., Iwanaga M., Mackenzie P.I., Nagata K., Yamazoe Y., Ogiri K., and Yamada H. Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. Mol. Pharmacol. 67 (2005) 665-672
44. Takeda S., Kitajima Y., Ishii Y., Nishimura Y., Mackenzie P.I., Oguri K., and Yamada H. Inhibition of UDP-glucuronosyltransferase 2B7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode. Drug Metab. Dispos. 34 (2006) 1277-1282
45. 9-Tetrahydrocannabinol enhances MCF-7 cell proliferation via cannabinoid receptor-independent signaling. Toxicology 245 (2008) 141-146
46. Takeda S., Misawa K., Yamamoto I., and Watanabe K. Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in cannabis. Drug Metab. Dispos. 36 (2008) 1917-1921
47. van Landeghem A.A., Poortman J., Nabuurs M., and Thijssen J.H. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res. 45 (1985) 2900-2906
48. von Bueren A.O., Schlumpf M., and Lichtensteiger W. Delta(9)-tetrahydrocannabinol inhibits 17beta-estradiol-induced proliferation and fails to activate androgen and estrogen receptors in MCF7 human breast cancer cells. Anticancer Res. 28 (2008) 85-89
49. Walsh D., Nelson K.A., and Mahmoud F.A. Established and potential therapeutic applications of cannabinoids in oncology. Support. Care Cancer 11 (2003) 137-143
50. Watanabe K., Motoya E., Matsuzawa N., Funahashi T., Kimura T., Matsunaga T., Arizono L., and Yamamoto I. Marijuana extracts possess the effects like the endocrine disrupting chemicals. Toxicology 206 (2005) 471-478
51. Yamaguchi Y., Takei H., Suemasu K., Kobayashi Y., Kurosumi M., Harada N., and Hayashi S. Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer. Cancer Res. 65 (2005) 4653-4662
52. Yue W., Wang J.P., Conaway M., Masamura S., Li Y., and Santen R.J. Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. Endocrinology 143 (2002) 3221-3229
53. Zhao Y., Agarwal V.R., Mendelson C.R., and Simpson E.R. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137 (1996) 5739-5742
54. Zhao X., Goswami M., Pokhriyal N., Ma H., Du H., Yao J., Victor T.A., Polyak K., Sturgis C.D., Band H., and Band V. Cancer Res. 68 (2008) 467-475 (Erratum in: Cancer Res. 68 (2008) 1609)
55. Zhou D.J., Pompon D., and Chen S.A. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res. 50 (1990) 6949-6954